<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39375365</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>COVID-19 mRNA booster vaccination induces robust antibody responses but few adverse events among SARS-CoV-2 naïve nursing home residents.</ArticleTitle><Pagination><StartPage>23295</StartPage><MedlinePgn>23295</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23295</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-73004-8</ELocationID><Abstract><AbstractText>Residents in nursing homes face heightened COVID-19 risks. We aimed to assess the adverse events (AEs) rates and antibody responses after the first to the fifth dose of COVID-19 mRNA vaccination in a nursing home cohort. Ninety-five SARS-CoV-2 naïve participants consisted of 26 staff (median age, 51 years) and 69 residents (median age, 88 years). Life-threatening AEs were reported in neither residents nor staff. The severity of non-life-threatening AEs was graded, and severe AEs were reported only in staff. The AEs rates were considerably lower in residents, compared to those in staff. Anti-RBD IgG and the neutralizing titers (NTs) against Wuhan and Omicron BA.4/BA.5 did not differ significantly between those with 'any AE' and 'no AE' among both staff and residents two months after the second, third and fifth doses, while the anti-RBD IgG significantly differed between two groups after third dose in residents. These findings suggest that the anti-RBD IgG and the NTs increase regardless of the occurrence of AEs. Our study underscores a robust antibody response in both in staff and residents, and fewer AEs following COVID-19 vaccination in SARS-CoV-2 naïve residents than staff, supporting the recommendation for mRNA booster doses in older adults at high-risk care facilities.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Itamochi</LastName><ForeName>Masae</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazawa</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saga</LastName><ForeName>Yumiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Virology, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimada</LastName><ForeName>Takahisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Virology, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Kosuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Research Planning, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maenishi</LastName><ForeName>Emi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Bacteriology, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isobe</LastName><ForeName>Junko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Bacteriology, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasajima</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawashiri</LastName><ForeName>Chikako</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tani</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Virology, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oishi</LastName><ForeName>Kazunori</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Toyama Institute of Health, 17-1 Nakataikoyama, Imizu, Toyama, 939-0363, Japan. toyamaeiken1@chic.ocn.ne.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021</GrantID><Agency>Kurozumi Medical Foundation</Agency><Country /></Grant><Grant><GrantID>2023</GrantID><Agency>Daido Life Insurance Company</Agency><Country /></Grant><Grant><GrantID>2021-14</GrantID><Agency>Daido Life Insurance Company</Agency><Country /></Grant><Grant><GrantID>2021</GrantID><Agency>Japan Society of Public Health</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000719227">COVID-19 vaccine booster shot</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Life-threatening adverse events</Keyword><Keyword MajorTopicYN="N">MRNA booster vaccination</Keyword><Keyword MajorTopicYN="N">Nursing home residents</Keyword><Keyword MajorTopicYN="N">Omicron variants</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375365</ArticleId><ArticleId IdType="pmc">PMC11458568</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-73004-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-73004-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>White, E. M. et al. Variation in SARS-CoV-2 prevalence in U.S. skilled nursing facilities. J. Am. Geriatr. Soc.68, 2167–2173 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404330</ArticleId><ArticleId IdType="pubmed">32674223</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu, K. et al. Epidemiology of SARS-CoV-2 infection in nursing facilities and the impact of their clusters in a Japanese core city. J. Infect. Chemother.28, 955–961 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005365</ArticleId><ArticleId IdType="pubmed">35461770</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura, K. et al. Impact of COVID-19 and closed transmission of SARS-CoV-2 during the first wave in Toyama Prefecture, Japan, March 30 to May 18, 2020. Jpn. J. Infect. Dis.77, 75–82 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">37914293</ArticleId></ArticleIdList></Reference><Reference><Citation>Comas-Herrera, A. et al. LT Covid International Living Report on COVID-19 and Long-Term Care (2022). https://ltccovid.org/international-living-report-covid-ltc/</Citation></Reference><Reference><Citation>Iritani, O. et al. Clusters of COVID-19 in long-term care hospitals and facilities in Japan from 16 January to 9 May 2020. Geriatr. Gerontol. Int.20, 715–719 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361521</ArticleId><ArticleId IdType="pubmed">32634849</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med.383, 2603–2615 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamprinou, M. et al. COVID-19 vaccines adverse events: Potential molecular mechanisms. Immunol. Res.71, 356–372 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9821369</ArticleId><ArticleId IdType="pubmed">36607502</ArticleId></ArticleIdList></Reference><Reference><Citation>Allergic Reactions including Anaphylaxis after receipt of Moderna COVID-19 Vaccine-United States. December 21, 2020–January 10, 2021. MMWR Morb Mortal. Wkly. Rep.70, 125–129 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7842812</ArticleId><ArticleId IdType="pubmed">33507892</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevorach, D. et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N. Eng. J. Med.385, 2140–2049 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531987</ArticleId><ArticleId IdType="pubmed">34614328</ArticleId></ArticleIdList></Reference><Reference><Citation>Pather, S. et al. SARS-CoV-2 omicron variants: Burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. Front. Immunol.14, 1130539 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10242031</ArticleId><ArticleId IdType="pubmed">37287979</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, H. J. et al. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nat. Commun.15, 1883 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10917753</ArticleId><ArticleId IdType="pubmed">38448400</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano, T. et al. Distinct immune cell dynamics corelate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine. Cell. Rep. Med.3, 100631 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9023335</ArticleId><ArticleId IdType="pubmed">35545084</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike, R. et al. Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination. Vaccines10, 451 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8950942</ArticleId><ArticleId IdType="pubmed">35335084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobashi, Y. et al. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine. PLOS ONE17, e0269917 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9187057</ArticleId><ArticleId IdType="pubmed">35687563</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, I. et al. Correlation between adverse events and antibody titers among healthcare workers vaccinated with BNT161b mRNA COVID-19 vaccine. Vaccines10, 1220 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9412348</ArticleId><ArticleId IdType="pubmed">36016109</ArticleId></ArticleIdList></Reference><Reference><Citation>Held, J. et al. Reactogenicity correlates only weakly with humoral immunogenicity after COVID-19 vaccination with BNT162b2 mRNA (Comirnaty). Vaccines9, 1063 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8539109</ArticleId><ArticleId IdType="pubmed">34696171</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani, N. et al. Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT612b2 mRNA. Vaccine40, 2062–2067 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8842119</ArticleId><ArticleId IdType="pubmed">35177298</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi, M., Higa, Y., Esaki, A., Nabeshima, Y. &amp; Nakazono, A. Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects? PLOS ONE16, e0257668 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8452080</ArticleId><ArticleId IdType="pubmed">34543337</ArticleId></ArticleIdList></Reference><Reference><Citation>Itamochi, M. et al. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort. Vaccine41, 2234–2242 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9968608</ArticleId><ArticleId IdType="pubmed">36858871</ArticleId></ArticleIdList></Reference><Reference><Citation>Canaday, D. H. et al. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents. EBiomedicine80, 104066 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9122310</ArticleId><ArticleId IdType="pubmed">35605428</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong, Y. et al. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents. Influ. Other Respir. Viruses16, 1066–1071 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9530588</ArticleId><ArticleId IdType="pubmed">35962568</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyebanji, O. A. et al. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents? Aging Clin. Exp. Res.33, 3151–3160 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8518269</ArticleId><ArticleId IdType="pubmed">34652783</ArticleId></ArticleIdList></Reference><Reference><Citation>Winokur, P. et al. Bivalent omicron BA.1-Adapted BNT162b2 booster in adults older than 55 years. N. Engl. J. Med.388, 214–227 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933930</ArticleId><ArticleId IdType="pubmed">36652353</ArticleId></ArticleIdList></Reference><Reference><Citation>Usdan, L. et al. A bivalent Omicron–BA.4/BA.5-Adapted BNT162b2 booster in ≥ 12-Year-Olds in. Clin. Infect. Dis.78, 1194–1203 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11093671</ArticleId><ArticleId IdType="pubmed">38016021</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias, S. et al. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: Phase 2/3 trial interim results. Nat. Med.29, 2325–2333 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504066</ArticleId><ArticleId IdType="pubmed">37653342</ArticleId></ArticleIdList></Reference><Reference><Citation>McConeghy, K. W. et al. Infections, hospitalizations, and deaths among US nursing home residents with vs without a SARS-CoV-2 vaccine booster. JAMA Netw. Open5, e2245417 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9856563</ArticleId><ArticleId IdType="pubmed">36477482</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel, R. et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent sever COVID-19 outcomes: A retrospective cohort study. Lancet Infect. Dis.23, 914–921 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10156150</ArticleId><ArticleId IdType="pubmed">37062302</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, E. et al. Effectiveness of up to date COVID-19 vaccination in preventing SARS-CoV-2 infection among nursing home residents–United States, November 29, 2022–. Wkly. Rep.72, 690–693 (2023). MMWR Morbid. Mortal.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10328477</ArticleId><ArticleId IdType="pubmed">37347711</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulop, T., Pawelec, G., Castle, S. &amp; Loeb, M. Immunosenescence and vaccination in nursing home residents. Clin. Infect. Dis.48, 443–448 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19140756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med.29, 344–347 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36473500</ArticleId></ArticleIdList></Reference><Reference><Citation>Amano, M. et al. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron. Sci. Rep.13, 17404 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10575932</ArticleId><ArticleId IdType="pubmed">37833390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayed, J. et al. Safety and immunogenicity of the monovalent Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in individuals ≥ 12 years old: A phase 2/3 trial. Vaccines12, 118 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10893482</ArticleId><ArticleId IdType="pubmed">38400102</ArticleId></ArticleIdList></Reference><Reference><Citation>The vaccination rates of COVID-19 vaccine. Cabinet Japan (2024). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/yobou-sesshu/syukeihou_00002.html</Citation></Reference><Reference><Citation>Hansen, C. H. et al. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: A national cohort study. Lancet Infect. Dis.24, e73–e74 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38190834</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration in US. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (2005). https://www.fda.gov/media/73679/download</Citation><ArticleIdList><ArticleId IdType="pubmed">37532612</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani, H. et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Virol. J.18, 16 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801864</ArticleId><ArticleId IdType="pubmed">33435994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>